Navigation Links
Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics
Date:2/11/2008

RICHMOND, Va., Feb. 11 /PRNewswire-FirstCall/ -- A report released today, commissioned by Insmed Inc. (Nasdaq: INSM), identifies potential cost savings of approximately $378 billion over the next 20 years from making follow on biologics (FOBs) available in the U.S.

The econometric study by economist Dr. Robert J. Shapiro, former Under Secretary of Commerce in the Clinton Administration, found that "...generic versions of the top 12 categories of biologic treatments with patent protections that have expired or that are due to expire in the near future could save Americans $67 billion to $108 billion over 10 years and $236 billion to $378 billion over 20 years."

According to other published reports, an estimated $10 billion worth of biologic drugs are expected to come off patent by 2010, with an additional $10 billion by 2015. FOBs would provide safe and effective therapies at a reduced cost following the expiration of the original product's patent.

Dr. Shapiro's report, entitled The Potential American Market for Generic Biological Treatments and the Associated Cost Savings, also finds that "...the economic and medical benefits from generic biologics should be as great or perhaps even greater as those from generic forms of traditional pharmaceuticals... Moreover, the potential savings from the discounted prices that generics provide will be larger with biogenerics, because original biologics are so much more expensive than other brand pharmaceuticals..."

The scientific, regulatory and legal framework for the approval of small- molecule generic drugs is well developed, and a regulatory system for approving FOBs was established in Europe in 2006. However, no regulatory pathway currently exists for FOBs, which are a
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... ... detection and quantification of partially hydrolyzed gluten in foods, has been accepted by ... the method “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” ...
(Date:7/30/2015)... Dallas, Texas (PRWEB) , ... July 30, 2015 , ... ... professional and in-depth study on the current state of the global Propanol market with ... are Sinopec, CNPC, BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal ...
(Date:7/30/2015)... ISN improves the efficiency and effectiveness of contractor management systems. ISN,s online contractor management platform, ... 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... Dallas, TX , ISN has additional offices in Calgary , ...
(Date:7/30/2015)... ... July 30, 2015 , ... GEA's ... designed for continuous operation up to 1500 bar. The sanitary design gauge of ... preventing toxic contamination. , The Pony™ NS2006L homogenizer is an ideal solution for ...
Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2
... ... The 2nd Algae World Europe conference in Brussels addresses ... engineering, marketing and financial aspects of the algae value chain. Panel ... biofuels and high-value co-products like pharmaceuticals, nutraceuticals, cosmetics, aquaculture feed, bioplastics, ...
... , , ... Ltd, a specialty,biopharmaceutical company focused on allergy, today announced ... in a,recently completed phase II clinical trial. Ragweed allergy ... of the population.,Circassia,s latest clinical results follow two earlier ...
... , , , , ... 3SBio Inc. (Nasdaq:, SSRX ), a leading biotechnology company ... in China ,today announced that it has submitted ... to the Chinese State Food and Drug Administration (SFDA).,NuPIAO ...
Cached Biology Technology:2nd Algae World Europe Tracks Algae Commercialization from Algae Production to High-value Products- Nutraceuticals, Aquaculture Feed, Cosmetics, Biofuels and More 22nd Algae World Europe Tracks Algae Commercialization from Algae Production to High-value Products- Nutraceuticals, Aquaculture Feed, Cosmetics, Biofuels and More 3Circassia Achieves Positive Phase II Clinical Results With Ragweed Allergy T-Cell Vaccine 2Circassia Achieves Positive Phase II Clinical Results With Ragweed Allergy T-Cell Vaccine 33SBio Inc. Submits Application for NuPIAO Phase I Clinical Trial 23SBio Inc. Submits Application for NuPIAO Phase I Clinical Trial 3
(Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION ... new convenient and secure method to make payments.  ... payment methods, introduced with its groundbreaking voice-direct payment ...
(Date:7/9/2015)... DUBLIN , July 07, 2015 ... has announced the addition of the "Biometrics ... and Forecasts 2015-2020" report to their offering. ... a major contributor to this growth and the ... US$5.5 billion in revenue for companies involved in ...
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, ... ), the leading developer of human interface ... authentication technology, the industry,s first fully hardware ... innovative Match-in-Sensor secure authentication technology is literally ... pattern storage and biometric matching within the ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... made progress since 2000, but an annual death toll of ... makes a comeback, the first joint malaria report from the ... says. , The report on the disease that claims three ... today at events in New York, Geneva and Cairo. , ...
... understand the complex processes in the human brain that lead to ... the brains of humans and bees don't look much alike. But ... scientists much about the workings of the primitive portion of our ... alcohol or other drugs. , This region of the brain exerts ...
... incidence of disease from HIV and hepatitis is increasing in ... patients undergoing surgery. Now, researchers have shown that nearly 40 ... patients who tested positive for a bloodborne germ. , "While ... precautions have been in effect for some time to prevent ...
Cached Biology News:Malaria killing a million a year 2Bees, Brains and Addiction 2Scalpel-free surgery could reduce risk of HIV and hepatitis exposure for health care workers 2
ANTI S. GROUP AG:H...
Recorder REC-111 single-channel, 1. Category: Chromatography Systems & Accessories, Systems....
For the quantitative determination of cyclic AMP (cAMP) concentrations in cell culture supernates, serum, plasma, saliva, urine and cell lysates....
... WR Cryoscope for molecular weight determinations for petroleum-based applications. Multiple solvents can be used, such ... ... ... ...
Biology Products: